{'fraction_non_alphanumeric': 0.02844950213371266, 'fraction_numerical': 0.005689900426742532, 'mean_word_length': 5.068965517241379, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of benign prostatic hyperplasia.

Medications to treat benign prostatic hyperplasia fall into two main categories: α1-adrenergic–antagonist drugs, which relax smooth muscle in the prostate, and drugs that inhibit 5α-reductase, which shrink the prostate by blocking the formation of the chief intracellular androgen, dihydrotestosterone.1 The main question is, Which drug is better, or would a combination of the two work best? In this issue of the Journal, Lepor et al. report the results of a landmark study by the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group that attempts to answer this question.2 The authors found that treatment with terazosin, an α . . .